Dupilumab

CHEBI:CHEBI_750639

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2583635
generic_name
Dupilumab
pharm_class
Interleukin 4 Receptor alpha Antagonists [MoA]
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
SUBCUTANEOUS
package_marketing_start_date
28-MAR-17
marketing_start_date
20210614
marketing_category
DRUG FOR FURTHER PROCESSING
nui
N0000193341
pharm_class_cs
Antibodies, Monoclonal [CS]
active_ingredient_strength
100 mg/.67mL
labeler_name
sanofi-aventis U.S. LLC
manufacturer_name
sanofi-aventis U.S. LLC
brand_name
Dupixent
brand_name_base
Dupixent
product_ndc
0024-5914
application_number
BLA761055
spl_id
e921faa5-f556-4d9b-b5d9-d2b467b94628
active_ingredient_name
DUPILUMAB
package_ndc
0024-5914-02
package_description
2 SYRINGE, GLASS in 1 CARTON (0024-5914-02) / 2 mL in 1 SYRINGE, GLASS (0024-5914-20)
unii
420K487FSG
spl_set_id
595f437d-2729-40bb-9c62-c8ece1f82780
pharm_class_epc
Interleukin-4 Receptor alpha Antagonist [EPC]
pharm_class_moa
Interleukin 4 Receptor alpha Antagonists [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class